Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Cidofovir
General information
Cidofovir ( S -1-3-hydroxy-2-phosphonylmethoxypropylcytosine), also known as HPMPC, is a nucleotide analogue with potent activity against cytomegalovirus (CMV) in vitro and in vivo.
Drug studies
Observational studies
Cidofovir has been used to treat 14 patients with cytomegalovirus infection after stem-cell transplantation; no adverse effects were reported in this small study [ ].
In an open study of the use of intralesional cidofovir in treating laryngeal papilloma, 14 adults received monthly injections of cidofovir (maximum dose 37.5 mg per injection in 6 ml of saline; mean 22.5 mg) [ ]. Remission was achieved in all cases with an average of six injections and without additional laryngeal scarring, vocal cord damage, or systemic adverse effects.
Topical intralaryngeal cidofovir has been used as an effective adjunct in treating recurrences of recurrent laryngeal papillomatosis, a benign laryngeal disease caused by human papilloma virus [ ]. In 10 patients with recurrent papillomatosis, cidofovir was injected with a laryngeal needle during papilloma resection. There were no local or systemic adverse effects, but the median interval between recurrences increased significantly from 102 days before cidofovir to 239 days after treatment.
Organs and systems
You're Reading a Preview
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here